• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

33.62 +2.42 (+7.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 06, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
November 04, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
October 27, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
October 21, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
October 21, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
October 20, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
October 19, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
September 29, 2025
RAPT on track to initiate trial this year 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
August 27, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
August 07, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
June 23, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
June 13, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Upcoming Investor Conferences
June 04, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports First Quarter 2025 Financial Results
May 08, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
April 15, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Upcoming Investor Conferences
March 07, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
March 06, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 09, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
January 06, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces $150 Million Private Placement
December 23, 2024
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
December 23, 2024
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
November 12, 2024
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
November 11, 2024
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
August 08, 2024
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
May 09, 2024
From Schall Law
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports First Quarter 2024 Financial Results
May 09, 2024
Company maintains solid cash position of $141.6 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
April 09, 2024
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
March 11, 2024
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 07, 2024
Company maintains solid cash position of $158.9 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap